Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women
This study was undertaken to explore whether the incidence of breast tumors that overexpress HER-2/neu protein product (HER-2/neu+) is more strongly associated with oral contraceptives (OCs) and other factors than is the incidence of tumors that do not (HER-2/neu-). In a population-based sample of women <45 years, 42.9% (159 of 371) of in situ and invasive breast cancer cases were HER-2/neu+ as assessed by immunohistochemistry in archived tissue. Polytomous logistic regression was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for HER-2/neu+ and HER-2/neu-breast cancer, as compared with 462 population-based controls, in relation to OCs and other factors. The ratio of the ORs (HER-2/neu+ versus HER-2/neu-tumors) was used as an indicator of heterogeneity in risk. There was little heterogeneity in risk for OC use of 6 months or more by HER-2/neu status (age-adjusted ratio of ORs, 1.29; 95% CI, 0.83-2.00). Among early pill users (< or =18 years of age) heterogeneity was apparent (2.39; 95% CI, 1.08-5.30), which was attenuated in a multivariate model (1.99; 95% CI, 0.87-4.54); among cases with estrogen receptor-negative tumors, heterogeneity increased to 5-fold. For other risk factors, there was no marked heterogeneity between + and - tumors for HER-2/neu. In summary, the incidence of breast cancer among younger women in relation to OC use at an early age varied with HER-2/neu status, with the odds ratio for +tumors twice that for -tumors.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1999 |
|---|---|
| Erschienen: |
1999 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 8(1999), 5 vom: 30. Mai, Seite 413-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gammon, M D [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 28.07.1999 Date Revised 20.11.2014 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM102827702 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM102827702 | ||
| 003 | DE-627 | ||
| 005 | 20231222125053.0 | ||
| 007 | tu | ||
| 008 | 231222s1999 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0343.xml |
| 035 | |a (DE-627)NLM102827702 | ||
| 035 | |a (NLM)10350436 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gammon, M D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.1999 | ||
| 500 | |a Date Revised 20.11.2014 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This study was undertaken to explore whether the incidence of breast tumors that overexpress HER-2/neu protein product (HER-2/neu+) is more strongly associated with oral contraceptives (OCs) and other factors than is the incidence of tumors that do not (HER-2/neu-). In a population-based sample of women <45 years, 42.9% (159 of 371) of in situ and invasive breast cancer cases were HER-2/neu+ as assessed by immunohistochemistry in archived tissue. Polytomous logistic regression was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for HER-2/neu+ and HER-2/neu-breast cancer, as compared with 462 population-based controls, in relation to OCs and other factors. The ratio of the ORs (HER-2/neu+ versus HER-2/neu-tumors) was used as an indicator of heterogeneity in risk. There was little heterogeneity in risk for OC use of 6 months or more by HER-2/neu status (age-adjusted ratio of ORs, 1.29; 95% CI, 0.83-2.00). Among early pill users (< or =18 years of age) heterogeneity was apparent (2.39; 95% CI, 1.08-5.30), which was attenuated in a multivariate model (1.99; 95% CI, 0.87-4.54); among cases with estrogen receptor-negative tumors, heterogeneity increased to 5-fold. For other risk factors, there was no marked heterogeneity between + and - tumors for HER-2/neu. In summary, the incidence of breast cancer among younger women in relation to OC use at an early age varied with HER-2/neu status, with the odds ratio for +tumors twice that for -tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a Americas | |
| 650 | 4 | |a Biology | |
| 650 | 4 | |a Breast Cancer | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Case Control Studies | |
| 650 | 4 | |a Contraception | |
| 650 | 4 | |a Contraceptive Methods | |
| 650 | 4 | |a Developed Countries | |
| 650 | 4 | |a Diseases | |
| 650 | 4 | |a Examinations And Diagnoses | |
| 650 | 4 | |a Family Planning | |
| 650 | 4 | |a Incidence | |
| 650 | 4 | |a Laboratory Examinations And Diagnoses | |
| 650 | 4 | |a Laboratory Procedures | |
| 650 | 4 | |a Measurement | |
| 650 | 4 | |a Neoplasms | |
| 650 | 4 | |a New Jersey | |
| 650 | 4 | |a North America | |
| 650 | 4 | |a Northern America | |
| 650 | 4 | |a Oral Contraceptives | |
| 650 | 4 | |a Research Methodology | |
| 650 | 4 | |a Research Report | |
| 650 | 4 | |a Risk Factors | |
| 650 | 4 | |a Studies | |
| 650 | 4 | |a United States | |
| 650 | 7 | |a Contraceptives, Oral |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Hibshoosh, H |e verfasserin |4 aut | |
| 700 | 1 | |a Terry, M B |e verfasserin |4 aut | |
| 700 | 1 | |a Bose, S |e verfasserin |4 aut | |
| 700 | 1 | |a Schoenberg, J B |e verfasserin |4 aut | |
| 700 | 1 | |a Brinton, L A |e verfasserin |4 aut | |
| 700 | 1 | |a Bernstein, J L |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, W D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology |d 1992 |g 8(1999), 5 vom: 30. Mai, Seite 413-9 |w (DE-627)NLM012651702 |x 1538-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:1999 |g number:5 |g day:30 |g month:05 |g pages:413-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 1999 |e 5 |b 30 |c 05 |h 413-9 | ||